Grant: Proof of Principle Program - Phase I

Refractory cancers are a major medical and societal problem. An estimated 73,800 deaths from cancer occurred in Canada in 2008. Approximately 4,000 Canadian women die from breast cancer annually and 35% of children with metastatic rhabdomyosarcoma do not survive 5 years. Addressing this mandates new therapeutic approaches. We identified Tdp1 as a target that has the potential to improve outcome in breast cancer and rhabdomyosarcoma. We have identified inhibitors of Tdp1 and propose to develop these with the objective of commercialization.